Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Cancer Commun (Lond). 2019 Sep 27;39(1):51. doi: 10.1186/s40880-019-0395-3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Female
  • Humans
  • Immunoglobulin D*
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / mortality
  • Risk Factors
  • Survival Analysis
  • Thalidomide / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • Immunoglobulin D
  • Thalidomide
  • Bortezomib
  • Lenalidomide